Healius Limited

HLS

AU0000033359

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-03 EDT			5-day change	1st Jan Change
1.33 ^AUD	+4.72%		+2.31%	-18.65%

05-28	Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit	CI
05-27	Healius Hires UBS to Sell Lumus Imaging	MT

Healius Limited Announces Cessation of Dr. Errol Katz as Director

November 24, 2019 at 07:16 pm

Healius Limited announced the cessation of Dr. Errol Katz as Director of the company, effective November 25, 2019.

Latest news about Healius Limited

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit	05-27	CI
Healius Hires UBS to Sell Lumus Imaging	05-26	MT
Healius Provides Updates on Strategic Review	05-26	CI
Healius Refinances Debt Facility to March 2027	05-13	MT
Healius Brings in UBS as It Reviews Strategy, Considers Asset Sales	03-11	CI
Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight	03-05	MT
Australia shares inch lower as miners weigh; GDP data in focus	03-04	RE
Healius Accelerates Strategic Review	03-04	CI
Jarden Research Adjusts Healius’ Price Target to AU$1.26 From AU$1.29, Keeps at Underweight	02-27	MT
Australian Shares Inch Up as Market Awaits Economic Data, US Fed Statements	02-27	MT
Healius Shares Sink 6%; Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss	02-26	MT
Healius Limited Provides Earnings Guidance for Second Half of 2024 and Fiscal Year 2024	02-26	CI
Transcript : Healius Limited, H1 2024 Earnings Call, Feb 27, 2024	02-26
Healius Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss	02-26	MT
Healius Reports Wider H1 FY24 Loss as Revenue Slips 2%	02-26	MT
Healius Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
Healius Subsidiary Enters Commercial Deal with Geneva-based SGS	02-06	MT
Australian shares on three-day winning streak; banks, miners lead	01-23	RE
Australia shares starts 2024 higher on rate-cut hopes	01-01	RE
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer	12-26	MT
Australian Clinical Labs Limited cancelled the acquisition of Healius Limited from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.	12-21	CI
Australian shares end higher on miners, Fed rate pivot	12-15	RE
US Fed's Dovish Stance Lifts Australian Shares	12-15	MT
Australian Clinical Labs Intends to Withdraw Proposed Healius Takeover	12-14	MT
Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius	12-14	MT

Healius Limited is a healthcare company. The Companyâs segments include Pathology, Imaging and Other. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment provides imaging services from standalone imaging sites, hospitals and medical centers. It has a network of pathology laboratories, collection centers and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. Its brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. Its Pathology operates 100 medical laboratories and 2,000 patient collection centers across metropolitan, regional and remote Australia. IQ Pathology is a specialized dermatopathology laboratory that provides comprehensive dermatopathology services Australia wide.

Sector

Healthcare Facilities & Services

Calendar

2024-08-20 - Q4 2024 Earnings Release (Projected)

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Healius Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

1.27 AUD

Average target price

1.372 AUD

Spread / Average Target

+8.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
HEALIUS LIMITED	-18.65%	612M
SONIC HEALTHCARE LIMITED	-24.66%	7.76B
RADNET, INC.	+68.65%	4.33B
SYNLAB AG	-3.33%	2.64B
DR. LAL PATHLABS LIMITED	+3.74%	2.63B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-46.17%	2.16B
NEOGENOMICS, INC.	-15.27%	1.75B
FLEURY S.A.	-22.12%	1.46B
METROPOLIS HEALTHCARE LIMITED	+13.62%	1.17B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.81%	1.14B

Medical & Diagnostic Laboratories

Healius Limited

Equities

HLS

AU0000033359

Healthcare Facilities & Services

Healius Limited Announces Cessation of Dr. Errol Katz as Director

Latest news about Healius Limited

Chart Healius Limited

Company Profile

Income Statement Evolution

Ratings for Healius Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical & Diagnostic Laboratories